EP3615048A2 - Préparation à plusieurs ingrédients pour la régénération des ongles des doigts et des orteils et procédé de préparation associé - Google Patents
Préparation à plusieurs ingrédients pour la régénération des ongles des doigts et des orteils et procédé de préparation associéInfo
- Publication number
- EP3615048A2 EP3615048A2 EP18752879.9A EP18752879A EP3615048A2 EP 3615048 A2 EP3615048 A2 EP 3615048A2 EP 18752879 A EP18752879 A EP 18752879A EP 3615048 A2 EP3615048 A2 EP 3615048A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- mixture
- amount
- emollient
- colostrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 210000004906 toe nail Anatomy 0.000 title claims abstract description 27
- 210000004905 finger nail Anatomy 0.000 title claims abstract description 26
- 239000004615 ingredient Substances 0.000 title claims abstract description 26
- 230000008929 regeneration Effects 0.000 title claims abstract description 26
- 238000011069 regeneration method Methods 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 100
- 210000003022 colostrum Anatomy 0.000 claims abstract description 46
- 235000021277 colostrum Nutrition 0.000 claims abstract description 46
- 239000003921 oil Substances 0.000 claims abstract description 34
- 235000019198 oils Nutrition 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000008367 deionised water Substances 0.000 claims abstract description 33
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 27
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000003974 emollient agent Substances 0.000 claims abstract description 24
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 24
- 239000002304 perfume Substances 0.000 claims abstract description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000283690 Bos taurus Species 0.000 claims abstract description 20
- 239000002562 thickening agent Substances 0.000 claims abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 16
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 16
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 13
- 239000000230 xanthan gum Substances 0.000 claims abstract description 13
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 13
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 13
- 239000003755 preservative agent Substances 0.000 claims abstract description 11
- 230000002335 preservative effect Effects 0.000 claims abstract description 11
- 240000007817 Olea europaea Species 0.000 claims abstract description 10
- 241000219100 Rhamnaceae Species 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- 239000008163 avocado oil Substances 0.000 claims abstract description 10
- 235000021302 avocado oil Nutrition 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 9
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 9
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 9
- 235000015165 citric acid Nutrition 0.000 claims abstract description 9
- 229940124274 edetate disodium Drugs 0.000 claims abstract description 9
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 9
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940032094 squalane Drugs 0.000 claims abstract description 9
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 8
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 8
- 229940043375 1,5-pentanediol Drugs 0.000 claims abstract description 8
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims abstract description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims abstract description 8
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims abstract description 8
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims abstract description 8
- 229940100524 ethylhexylglycerin Drugs 0.000 claims abstract description 8
- 229940087305 limonene Drugs 0.000 claims abstract description 8
- 235000001510 limonene Nutrition 0.000 claims abstract description 8
- 229930007744 linalool Natural products 0.000 claims abstract description 8
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 8
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 7
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- 235000013336 milk Nutrition 0.000 claims abstract description 4
- 239000008267 milk Substances 0.000 claims abstract description 4
- 210000004080 milk Anatomy 0.000 claims abstract description 4
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 11
- 238000007792 addition Methods 0.000 claims description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- -1 conditioners Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 239000012258 stirred mixture Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 1
- 239000011369 resultant mixture Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 12
- 210000000282 nail Anatomy 0.000 description 38
- 239000003925 fat Substances 0.000 description 23
- 201000004681 Psoriasis Diseases 0.000 description 15
- 208000006187 Onycholysis Diseases 0.000 description 14
- 210000004904 fingernail bed Anatomy 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000026721 nail disease Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical group CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010028692 Nail discolouration Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028703 Nail psoriasis Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229940093903 antiseptics and corticosteroids Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000024755 nail discoloration Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 201000005976 yellow nail syndrome Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Definitions
- the invention refers to a multi-ingredient preparation for finger and toe nail regeneration and a method of preparation thereof.
- the main purpose for which the multi-ingredient preparation for finger and toe nail regeneration according to the invention may be used is the treatment and regeneration of finger and toe nails affected by onycholysis of finger and toe nails, as well as the treatment of nails affected by other conditions causing psoriasis .
- erosions are spot pits, mostly small and shallow, of various size, depth and shape. They form in psoriasis lesions in the back part of the matrix (area where a nail forms) . Most erosions are superficial, however if extensive, they may result in serious color and structure anomalies and may lead to nail brittleness. In the histological sense, erosions are a defect of the nail plate surface but when psoriasis is more advanced, an erosion may enlarge and result in a hole in the nail plate .
- a typical symptom is leukonychia (white spots on the nail) if the condition affects nail matrix, or salmon pink discoloration if nail bed is affected. Psoriasis in the nail bed results in oval oily salmon pink spots of various size.
- Onycholysis manifests itself in an irregular border between the pink part of the nail plate and its white edge when it pulls away from the nail bed. This condition occurs mainly when oily spots occur under nail plate, medially or on the side.
- a nail affected by onycholysis is yellowish as air and scales accumulate under its surface.
- the cause of nail detachment is often unknown. It is known that correctly formed nail bed does not have the granular layer of epidermal cells present as keratinocytes . Each process disturbing the formation of the nail bed, including also psoriasis, may contribute to the formation of the granular layer in nail bed which in consequence leads to onycholysis. Taking into account the cause behind this symptom, we can distinguish between primary onycholysis i.e. idiopathic of unknown cause, and secondary onycholysis .
- Primary onycholysis is often observed in people overusing nail treatment such as manicure, moisturizers, or using solvents included in cosmetics. Similarly, primary onycholysis is more often found in people with excessively long nails in whom even a smallest injury may cause the condition .
- compositions for treating nail conditions such as bacterial infections, infections caused by unknown substances, psoriasis infections and other nail inflammatory conditions.
- the composition includes a carrier system for the permeation of active compounds such as for instance fatty acid, its ester or polypropylene glycol, and active compounds such as antimycotics e.g. fluconazole, antibiotics, antiseptics or corticosteroids, and other enhancing additives.
- active compounds such as for instance fatty acid, its ester or polypropylene glycol
- active compounds such as antimycotics e.g. fluconazole, antibiotics, antiseptics or corticosteroids, and other enhancing additives.
- Such compositions are prepared in the form of tinctures, emulsions, solutions, ointments, creams or pastes.
- European patent EP 0913154 discloses a nail varnish for the treatment of psoriasis of the nails comprising an active substance i.e. corticosteroid being a strong antiinflammatory agent, and salicylic acid and other additives.
- an active substance i.e. corticosteroid being a strong antiinflammatory agent, and salicylic acid and other additives.
- European patent EP 1680076 discloses pharmaceutical and cosmetic compositions for treating nails containing compounds of the general formula R-O-Ri, wherein R is a linear or branched alkyl group comprising 5-8 carbon atoms and Ri is a formyl or an acetate group which have an excellent capacity of penetration through the keratinized nail substance and the adjacent skin, but they also have the ability to transport both therapeutic active substances such as antifungals, antibiotics, antiseptics and corticosteroids, as well as substances appropriate for nail care such as nutrients and building blocks.
- R-O-Ri wherein R is a linear or branched alkyl group comprising 5-8 carbon atoms and Ri is a formyl or an acetate group which have an excellent capacity of penetration through the keratinized nail substance and the adjacent skin, but they also have the ability to transport both therapeutic active substances such as antifungals, antibiotics, antiseptics and corticosteroids, as well as substances appropriate for nail care such as nutrients and building blocks.
- European patent EP 2117565 discloses the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, for the preparation of a medication, or a medical device, or a sanitary product, or a cosmetic, in the form of a nail lacquer, useful for the topical treatment of inflammatory diseases of the nails, such as psoriasis, lichen planus and atopic dermatitis .
- Prior art does not disclose an efficient agent for topical treatment of nail diseases or topical nail care which contains a carrier transporting an active substance required for a long-term success of the therapy through the nail to the nail bed and nail root (matrix) .
- the objective of this invention is to develop a multi- ingredient preparation to be used in a composition which during the described combined topical/systemic treatment of nail psoriasis, including treatment of onycholysis, does not have the defects known from prior art.
- lyophilized fat colostrum have the capacity to penetrate finger and toe nails, and to successfully treat infections causing nail inflammatory disorders, and in particular to successfully treat onycholysis.
- An important ingredient of the lyophilized fat colostrum commercially called cream colostrum is fat from bovine colostrum containing over 250 highly-concentrated compounds - not found in any other product of natural origin.
- a multi-ingredient preparation for finger and toe nail regeneration according to the invention contains: 2.00% to 8.00% by weight of active substance in the form of lyophilized fat colostrum containing 30% to 50% of fat from bovine colostrum; preferably the fat from bovine colostrum is cow colostrum milk.
- Commercial name of fat colostrum is Cream Colostrum; and as emulsifiers, emollients, antioxidants, conditioners, thickeners and other necessary substances such as:
- an emulsifier in the form of a mixture containing 50% to 70% by weight of cetearyl olivate and 30% to 50% by weight of sorbitan olivate.
- Commercial name of this emulsifier is Olivem 1000;
- an emulsifier in the form of glyceryl stearate.
- Commercial name of this emulsifier is Cutina GMS V;
- an emulsifier in the form of glyceryl tristearate (stearin).
- stearin Commercial name of this emulsifier is Crodamol GTIS;
- sodium polyacrylate Commercial name of this thickener is Cosmedia SP; 0.05% to 1.50% by weight of an antioxidant being a mixture of 69% by weight of polyethylene glycol with 24% by weight of vitamin E, with 5% by weight of ascorbyl palmitate, with 1% by weight of ascorbic acid with 1% by weight of citric acid.
- an antioxidant being a mixture of 69% by weight of polyethylene glycol with 24% by weight of vitamin E, with 5% by weight of ascorbyl palmitate, with 1% by weight of ascorbic acid with 1% by weight of citric acid.
- Oxynex K liquid Commercial name of the antioxidant is Oxynex K liquid;
- antioxidant 0.50% to 2.00% by weight of antioxidant being vitamin E
- a conditioner being pentylene glycol.
- Commercial name of this conditioner is Hydrolite 5;
- a preservative being a mixture of 90% by weight of phenoxyethanol with 10% by weight of ethylhexylglycerin .
- Commercial name of this preservative is Euxyl PE 9010;
- perfume composition containing perfume with limonene with an addition of linalool.
- perfume composition is Babynours Natflor RS27147/03;
- a multi-ingredient preparation for the regeneration of finger and toe nails contains a solvent in the form of deionized water.
- the formula of a multi-ingredient preparation for finger and toe nail regeneration is based on liquid crystal emulsions, thanks to which penetration of active ingredients is effective due to their lamellar structure.
- a multi-ingredient preparation for finger and toe nail regeneration contains olive squalane and valuable oils such as buckthorn oil and avocado oil, which are known for their regenerating properties.
- Lyophilized fat colostrum contains at least 30% to 50% of fat from bovine colostrum obtained no later than two hours from the termination of delivery.
- Lyophilized fat colostrum is a basic component of a multi-ingredient preparation for finger and toe nail regeneration, in particular for nails affected by onycholysis.
- the biggest advantage of the colostrum lies in proteins it contains such as immunoglobulin, lactoferrin, lysozyme or lactoperoxidase . These substances show strong antibacterial, antiviral and antifungal properties.
- Bovine colostrum also contains fats, carbohydrates, growth factors and derivatives of nucleic acids and easily digestible calcium. Fat colostrum is also characterized by high content of vitamins from group B and A, D and E.
- a multi-ingredient preparation for finger and toe nail regeneration according to the invention contains :
- lyophilized colostrum containing 30% to 50% fat from bovine colostrum.
- the content of fat from bovine colostrum is 40% and preferably the bovine colostrum is the cow milk colostrum.
- Commercial name of fat colostrum is Cream Colostrum;
- Commercial name of this emulsifier is Olivem 1000;
- emulsifier in the form of glycerol stearate.
- Commercial name of this emulsifier is Cutina GMS V;
- emollient in the form of glycerol tristearate stearin.
- commercial name of this emollient is Crodamol GTIS;
- % by weight of an emollient in the form of avocado oil % by weight of an emollient in the form of buckthorn oil ;
- polyacrylate polyacrylate .
- Commercial name of this thickener is Cosmedia SP;
- an antioxidant being a mixture of 69% by weight of polyethylene glycol with 24% by weight of vitamin E with 5% by weight of ascorbyl palmitate, with 1% by weight of ascorbic acid with 1% by weight of citric acid.
- Commercial name of the antioxidant is Oxynex K liquid;
- % by weight of a conditioner in the form of pentylene glycol % by weight of a conditioner in the form of pentylene glycol.
- Commercial name of this conditioner is Hydrolite 5;
- % by weight of a conditioner in the form of propanediol % by weight of a conditioner in the form of propanediol.
- Commercial name of this conditioner is Zernea;
- a preservative being a mixture of 90% by weight of phenoxyethanol with 10% by weight of ethylhexylglycerin .
- Commercial name of this preservative is Euxyl PE 9010;
- Babynours Natflor RS27147/03 and up to 100% by weight of a complementary solvent being deionized water.
- a method of preparation of a multi-ingredient preparation for finger and toe nail regeneration according to the invention consists in the preparation of a hot oil phase of the preparation in a container with a stirrer.
- Components constituting the oil phase in the formula of the preparation are pre-weighed according to the invention in % by weight. Stirring and heating up of the components of the oil phase up to the temperature of 80 °C is performed in a container with a stirrer.
- Pre-weighed components of the oil phase in the following amounts are added to the container with the stirrer in the following proportins: 2.00% to 5.00% of a mixture of cetearyl olivate with sorbitan olivate;
- the oil phase is continously stirred.
- a temperature of the stirred oil phase reaches approx. 70°C-78°C, the following components are added in weighed % by weight:
- deionized water pre-heated to 75°C - 80 °C in the amount of 95% of the total volume of deionized water resulting from the volume of components is added to the mixer preheated to 75°C. Then the following components weighed in % by weight are added to the mixer with heated deionized water:
- the stirrer of the mixer is activated, its speed is set preferably at 30 revolutions per minute, and at the same time the mixer heating system is activated.
- the mixture in the mixer is heated up to 80°C.
- another conditioner in the form of pentylene glycol in the amount of 2.00% to 5.00% by weight is added to the continuously stirred and heated mixture.
- the container with the stirrer containing the oil phase with a thickener and an emollient heated up to 80°C is connected with a tight pipe to a mixer containing a mixture of deionized water with conditioner and the chelating substance heated up to 80°C.
- a vacuum pump connected to the mixer is activated and a negative pressure of 0.02 MPa to 0.06 MPa is obtained inside the mixer.
- the value of negative pressure inside the mixer remains at the level of 0.04 MPa.
- Negative pressure value ranging from -0.02 MPa to -0.06 MPa makes it possible to suction the entire oil phase from the container with the stirrer to the mixer with the deionized water and added components.
- the mixture obtained together with the stirrer is cooled to a temperature of approx. 60°C. 1.70% to 2.20% by weight of an emollient in the form of glycerol trxstearate is poured into a separate vessel to which 0.05% to 1.00% by weight of a thickener in the form of xanthan gum powder is added and the components undergo stirring.
- the process of stirring xanthan gum with glycerol tristearate results in dispersion being a suspension of xanthan gum in a liquid emollient.
- Dispersion or a disperse system of xanthan gum with glycerol tristearate is a suspension of two phases of which one phase is a finely divided xanthan gum which is dispersed in the second phase i.e. glycerol tristearate, referred to as continuous phase.
- Fat colostrum is dissolved in a separate vessel in the remaining amount of deionized water making up for 5% by weight of total amount of deionized water resulting from the quantitative composition of components and is added to the mixture cooled to approx. 40°C, and the mixture undergoes stirring for 10 minutes with stirrer speed preferably at 40 revolutions per minute. The mixture and the stirrer are then cooled to approx. 30°C.
- a preservative being a mixture of phenoxyethanol with ethylhexylglycerin and 0.10% to 0.40% by weight of a perfume composition containing perfume with limonene with an addition of linalool is added to the mixture cooled to approx.
- the mixture again undergoes stirring with mixer speed preferably at 40 revolutions per minute.
- pH value of the mixture is measured.
- the pH value of the mixture being a multi-ingredient preparation for finger and toe nail regeneration is 6.0 to 6.5. If the pH value after the measurement is lower than 6.0, the mixture in the mixer undergoes neutralization by adding 20% solution of sodium hydroxide in the amount making it possible to achieve pH value of 6.0 to 6.5. Once the neutralizer is added, the mixture in the mixer again undergoes homogenization by activating the homogenizer set preferably at 1500 revolutions per minute for approx. 30 seconds and then the value of pH is checked again.
- a ready multi-ingredient preparation for finger and toe nail regeneration is poured into a temporary vessel and is then is portioned and packaged for sale.
- the advantage of the multi-ingredient preparation for finger and toe nail regeneration is permanent regeneration of nail bed, and in consequence disappearance of onycholysis, bigger elasticity of the plate, proper nourishment of nail tissue, stimulated nail plate growth and restoration of proper color to nails treated with multi-ingredient preparation for nail regeneration.
- Example kg set of the following components was prepared:
- an ani-oxidant in the form of a mixture of polyethylene glycol, vitamin E, ascorbyl palmitate, ascorbic acid and citric acid;
- An amount of 10 kg of pre-weighed components of the oil phase was poured into a 100 1 melter, said oil phase composed of a mixture of cetearyl olivate with sorbitan olivate from olive squalane and from avocado oil.
- a stirrer was started up with a speed of 30 rotations per minute.
- the melter was heated with an oil phase inside for a time of 40 minutes until a temperature of 80 °C was reached.
- the mixture was stirred for 2 minutes and the stirrer was turned off. Then, for 5 minutes, a homogenizer preset to 2000 revolutions per minute was activated in the mixer. After homogenization process was completed, the mixer with the mixture inside was cooled to 60 °C. Cooling time was 10 minutes.
- dispersion was prepared of 0.05 kg of xanthan gum mixed in 2.00 kg of glycerol tristearate .
- This dispersion was added to a mixture cooled to 60 °C, which was inside the mixer, and the mixture and the dispersion were homogenized again for approx. 2 minutes in a homogenizer preset to 2000 revolutions per minute.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL422524A PL233616B1 (pl) | 2017-08-10 | 2017-08-10 | Preparat do paznokci, dloni i stop oraz sposob wytwarzania tego preparatu |
| PCT/PL2018/000072 WO2019031976A2 (fr) | 2017-08-10 | 2018-07-12 | Préparation à plusieurs ingrédients pour la régénération des ongles des doigts et des orteils et procédé de préparation associé |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3615048A2 true EP3615048A2 (fr) | 2020-03-04 |
Family
ID=63165434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18752879.9A Withdrawn EP3615048A2 (fr) | 2017-08-10 | 2018-07-12 | Préparation à plusieurs ingrédients pour la régénération des ongles des doigts et des orteils et procédé de préparation associé |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3615048A2 (fr) |
| PL (1) | PL233616B1 (fr) |
| WO (1) | WO2019031976A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL447691A1 (pl) * | 2024-02-02 | 2025-08-04 | Yokaba Spółka Z Ograniczoną Odpowiedzialnością | Preparat do regeneracji paznokci i sposób otrzymywania preparatu |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637075B2 (en) * | 2008-09-12 | 2014-01-28 | Pharma Gp Aps | Colostrum composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4449497A (en) | 1996-10-16 | 1998-05-11 | Ipr-Institute For Pharmaceutical Research Ag | New carrier systems |
| RO118174B1 (ro) | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Lac de unghii şi utilizarea acestuia |
| WO2005018585A1 (fr) | 2003-08-25 | 2005-03-03 | Bioequal Ag | Formulations pharmaceutiques et cosmetiques pour le traitement des ongles |
| EP1958639A1 (fr) | 2007-02-14 | 2008-08-20 | Polichem S.A. | Utilisation de chitosanes dans le traitement de maladies inflammatoires des ongles |
| WO2010018418A1 (fr) * | 2008-08-12 | 2010-02-18 | Novatech D.O.O. | Formulation à base de clinoptilolite micronisée utilisée en tant qu’agent thérapeutique produisant un silicium extrêmement biodisponible |
| GB2507919A (en) * | 2011-08-25 | 2014-05-14 | Lillian M Day | Tripartite bioactive composition providing anti-oxidant and anti-inflammatory effects with immune system and stem cell produc tion enhancement |
| CN104306310A (zh) * | 2014-11-14 | 2015-01-28 | 成都鹏翔生物科技有限公司 | 一种含梣叶提取物的滋润护肤乳液及其制备方法 |
| CN104323967B (zh) * | 2014-11-14 | 2017-01-18 | 成都鹏翔生物科技有限公司 | 一种含丝茅提取物的保湿护肤乳液及其制备方法 |
-
2017
- 2017-08-10 PL PL422524A patent/PL233616B1/pl unknown
-
2018
- 2018-07-12 WO PCT/PL2018/000072 patent/WO2019031976A2/fr not_active Ceased
- 2018-07-12 EP EP18752879.9A patent/EP3615048A2/fr not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637075B2 (en) * | 2008-09-12 | 2014-01-28 | Pharma Gp Aps | Colostrum composition |
Also Published As
| Publication number | Publication date |
|---|---|
| PL233616B1 (pl) | 2019-11-29 |
| PL422524A1 (pl) | 2019-02-11 |
| WO2019031976A9 (fr) | 2019-12-19 |
| WO2019031976A2 (fr) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU782515B2 (en) | Pharmaceutical and cosmetic carrier or composition for topical application | |
| US8512718B2 (en) | Pharmaceutical composition for topical application | |
| JP2016130224A (ja) | 外用組成物 | |
| US20250127822A1 (en) | Topical composition comprised of cod liver oil for treating wounds and skin disorders | |
| WO1995019762A1 (fr) | Preparation dermatologique | |
| JP6726498B2 (ja) | 外用組成物 | |
| EP3615048A2 (fr) | Préparation à plusieurs ingrédients pour la régénération des ongles des doigts et des orteils et procédé de préparation associé | |
| CN106344589B (zh) | 一种稳定性改善的卡泊三醇倍他米松组合物 | |
| WO2013119144A2 (fr) | Produit de croissance capillaire (et variante) et procédé de traitement de la calvitie | |
| JPS61204109A (ja) | 乳化型の外用組成物 | |
| EP3411014A1 (fr) | Nouvelles compositions topiques comprenant de l'acide usnique et leur utilisation thérapeutique | |
| TWI718574B (zh) | 含有亞油酸的組成物 | |
| JP5824323B2 (ja) | 油中水型乳化組成物 | |
| JP7092494B2 (ja) | 油中水型乳化組成物 | |
| JP6779730B2 (ja) | 外用組成物 | |
| JP2018002686A (ja) | 内出血治療用製剤 | |
| JP7709827B2 (ja) | 外用組成物 | |
| JP6774767B2 (ja) | 皮膚外用剤組成物 | |
| WO2016071474A1 (fr) | Procédé de préparation d'un excipient approprié à la préparation de crèmes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20191008 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| R17D | Deferred search report published (corrected) |
Effective date: 20191219 |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20220316 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20220420 |